Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer (vol 7, pg 173, 2011)

被引：0
|
作者：
Oakman, C.
Moretti, E.
Santarpia, L.
Di Leo, A.
机构：
来源：
FUTURE ONCOLOGY | 2011年 / 7卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：803 / 806
页数：4
相关论文
共 50 条
  • [41] Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials
    Regan, Meredith M.
    Pagani, Olivia
    Fleming, Gini F.
    Walley, Barbara A.
    Price, Karen N.
    Rabaglio, Manuela
    Maibach, Rudolf
    Ruepp, Barbara
    Coates, Alan S.
    Goldhirsch, Aron
    Colleoni, Marco
    Gelber, Richard D.
    Francis, Prudence A.
    BREAST, 2013, 22 (06): : 1094 - 1100
  • [42] ECONOMIC EVALUATION OF FULVESTRANT 500MG FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER WHO HAVE PROGRESSED ON ENDOCRINE THERAPY
    Polanco, A. C.
    Salazar, A.
    Soto, H.
    Pizarro, M.
    VALUE IN HEALTH, 2014, 17 (03) : A87 - A87
  • [43] CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
    Regan, Meredith M.
    Leyland-Jones, Brian
    Bouzyk, Mark
    Pagani, Olivia
    Tang, Weining
    Kammler, Roswitha
    Dell'Orto, Patrizia
    Biasi, Maria Olivia
    Thuerlimann, Beat
    Lyng, Maria B.
    Ditzel, Henrik J.
    Neven, Patrick
    Debled, Marc
    Maibach, Rudolf
    Price, Karen N.
    Gelber, Richard D.
    Coates, Alan S.
    Goldhirsch, Aron
    Rae, James M.
    Viale, Giuseppe
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06): : 441 - 451
  • [44] Cost effectiveness of fulvestrant as an additional endocrine step in the treatment sequence for hormone responsive advanced breast cancer
    Hirsch, M. W.
    Gait, C.
    Chambers, J.
    VALUE IN HEALTH, 2006, 9 (06) : A288 - A288
  • [45] Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer according to body mass index
    Gevorgyan, A.
    Ganzinelli, M.
    Martinetti, A.
    Lo Vullo, S.
    Mariani, L.
    Festinese, F.
    Sottotetti, E.
    Ferrari, B.
    Galli, G.
    de Braud, F.
    Di Cosimo, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 12 - 13
  • [46] Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer according to prior therapy.
    De Angelis, Carmine
    Cerillo, Ivana
    Ruocco, Raffaella
    Bruzzese, Dario
    Forestieri, Valeria
    Lauria, Rossella
    Stanzione, Brigida
    Paciolla, Immacolata
    De Laurentiis, Michelino
    De Placido, Sabino
    Arpino, Grazia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women
    Vergote, I
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S57 - S58
  • [48] Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review
    Flemming, Jennifer
    Madarnas, Yolanda
    Franek, Jacob A.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) : 255 - 268
  • [49] Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review
    Jennifer Flemming
    Yolanda Madarnas
    Jacob A. Franek
    Breast Cancer Research and Treatment, 2009, 115
  • [50] Fulvestrant (Faslodex®) is effective in postmenopausal women with visceral metastases (VM) In advanced breast cancer (ABC)
    Mauriac, L
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S96 - S96
12345